FGF23 and chronic kidney disease: In contrast, another study conducted in 2544 Canadian patients with CKD estimated that the measurement of new biomarkers such as FGF23 does not imply an improvement in the prediction of RTT when added to conventional risk factors; however, it improved the prediction of death at one year [131].